Technical Analysis for IMU - Imugene Limited
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 3.80% | |
| Narrow Range Bar | Range Contraction | -1.20% | |
| Wide Bands | Range Expansion | -1.20% | |
| Narrow Range Bar | Range Contraction | -3.53% | |
| Wide Bands | Range Expansion | -3.53% | |
| Oversold Stochastic | Weakness | -3.53% | |
| Lower Bollinger Band Walk | Weakness | -3.53% | |
| Wide Bands | Range Expansion | -3.53% | |
| Lower Bollinger Band Touch | Weakness | -3.53% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 13 hours ago |
| Rose Above 10 DMA | about 16 hours ago |
| 10 DMA Resistance | about 17 hours ago |
| Up 5% | about 17 hours ago |
| 1.5x Volume Pace | about 17 hours ago |
Get this analysis on your stocks daily!
Imugene Limited Description
Imugene Limited is an immuno-oncology focused biopharmaceutical company. The Company is engaged in the research and development of human epidermal growth factor receptor 2 positive (HER2 +ve), and gastric and breast cancer vaccines. The Company is also engaged in the research, development and commercialization of health technologies. HER-Vaxx is a cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has completed a Phase I clinical trial with over 10 HER-2 positive patients with metastatic breast cancer. It was shown in pre-clinical studies and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu. HER-Vaxx has stimulated the production of HER-2 antibodies in early-stage cancer patients enrolled in the initial clinical trial. The Company is also developing mimotope-based immunotherapies against validated and oncology targets.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Gas Medicine Pharmaceutical Cancer Clinical Trial Biopharmaceutical Cancers Therapy Breast Cancer Oncology Tumor Tumors Biotechnology Companies Cancer Immunotherapy Health Technologies Antibodies Cancer Treatments Her2/Neu Immunotherapy Metastatic Breast Cancer Pancreatic Cancers
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.15 |
| 52 Week Low | 0.039 |
| Average Volume | 15,893,856 |
| 200-Day Moving Average | 0.088 |
| 50-Day Moving Average | 0.104 |
| 20-Day Moving Average | 0.093 |
| 10-Day Moving Average | 0.083 |
| Average True Range | 0.007 |
| RSI (14) | 41.52 |
| ADX | 32.79 |
| +DI | 10.931 |
| -DI | 34.091 |
| Chandelier Exit (Long, 3 ATRs) | 0.092 |
| Chandelier Exit (Short, 3 ATRs) | 0.090 |
| Upper Bollinger Bands | 0.115 |
| Lower Bollinger Band | 0.070 |
| Percent B (%b) | 0.26 |
| BandWidth | 48.596 |
| MACD Line | -0.007 |
| MACD Signal Line | -0.007 |
| MACD Histogram | -0.0006 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.090 | ||||
| Resistance 3 (R3) | 0.089 | 0.087 | 0.088 | ||
| Resistance 2 (R2) | 0.087 | 0.085 | 0.087 | 0.088 | |
| Resistance 1 (R1) | 0.084 | 0.084 | 0.086 | 0.085 | 0.087 |
| Pivot Point | 0.082 | 0.082 | 0.082 | 0.082 | 0.082 |
| Support 1 (S1) | 0.079 | 0.080 | 0.081 | 0.080 | 0.077 |
| Support 2 (S2) | 0.077 | 0.079 | 0.077 | 0.076 | |
| Support 3 (S3) | 0.074 | 0.077 | 0.076 | ||
| Support 4 (S4) | 0.075 |
